Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells

Cancer Research

Volumn 65, Issue 3, 2005, Pages 840-849

  Trost, Tatjana M ^a   Lausch, Ekkehart U ^a   Fees, Stephan A ^a   Schmitt, Steifen ^a   Enklaar, Thorsten ^a   Reutzel, Dirk ^a   Brixel, Lili R ^a   Schmidtke, Peter ^a   Maringer, Marko ^a   Schiffer, Ilka B ^a   Heimerdinger, Carolin K ^a   Hengstler, Jan G ^b   Fritz, Gerhard ^a   Bockamp, Ernst O ^a   Prawitt, Dirk ^a   Zabel, Bernhard U ^a   Spangenberg, Christian ^a,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; RETROVIRUS VECTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CARCINOMA CELL; CELL CYCLE; CELL LINE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALIGNANT TRANSFORMATION; MOLECULAR MODEL; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENESCENCE; UPREGULATION;

BREAST NEOPLASMS; CELL AGING; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 13444309091     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Baselga J, Norton L. Focus on breast cancer. Cancer Cell 2002;1:319-22.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 1990;50:421-5.
5. Sauter G, Moch H, Moore D, et al. Heterogeneity of erb B-2 gene amplification in bladder cancer. Cancer Res 1993;53:2199-203.
6. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-68.
7. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
8. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989;57:931-6.
9. Kiguchi K, Bol D, Carbajal S, et al. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 2000;19:4243-54.
10. Moody SE, Sarkisian CJ, Hahn KT, et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002;2:451-61.
11. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20:3210-23.
12. 1 cell cycle regulators in breast tumour cells. Oncogene 2000;19:1647-56.
13. Timms JF, White SL, O'Hare MJ, Waterfield MD. Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 2002;21:6573-86.
14. Schiffer IB, Gebhard S, Heimerdinger CK, et al. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. Cancer Res 2003;63:7221-31.
15. Weinberg HA. The cat and mouse games that genes, viruses, and cells play. Cell 1997;88:573-5.
16. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:S27-31.
17. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003;63:2705-15.
18. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
19. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
20. Stewart SA, Weinberg RA. Senescence: does it all happen at the ends? Oncogene 2002;21:627-30.
21. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
22. Deng Q, Liao R, Wu BL, Sun P. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004;279:1050-9.
23. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19.
24. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5598-611.
25. Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997;17:5588-97.
26. Zhu J, Woods D, McMahon M, Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997-3007.
27. Wang W, Chen JX, Liao R, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002;22:3389-403.
28. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995;268:1766-9.
29. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83.
30. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57.
31. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998;94:715-25.
32. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
33. Spangenberg C, Winterpacht A, Zabel BU, Lobbert RW. Cloning and characterization of a novel gene (TM7SF1) encoding a putative seven-pass transmembrane protein that is upregulated during kidney development. Genomics 1998;48:178-85.
34. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002;62:3126-31.
35. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 1993;90:8392-6.
36. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990;18:3587-96.
37. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 2000;97:7963-8.
38. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
39. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998;8:351-4.
40. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002;62:1876-83.
41. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
42. El Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
43. Xiao H, Hasegawa T, Miyaishi O, Ohkusu K, Isobe K. Sodium butyrate induces N1H3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner. Biochem Biophys Res Commun 1997;237:457-60.
44. Park JW, Jang MA, Lee YH, Passaniti A, Kwon TK. p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochem Biophys Res Commun 2001;280:244-8.
45. Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 2003;8:131-44.
46. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000;25:257-60.
47. Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91.
48. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003;5:R242-9.
49. Bacus SS, Altomare DA, Lyass L, et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002;21:3532-40.
50. Dickman S. Antibodies stage a comeback in cancer treatment. Science 1998;280:1196-7.
51. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-9.